Immunovia Publishes Interim Report January-March 2022
January-March · Net sales amounted to kSEK 182 (123) divided between sales of tests kSEK 122 (0) and royalties kSEK 60 (123) · Net earnings amounted to MSEK -44 (-23) and earnings per share before and after dilution were SEK -1.95 (-1.04) · Cash flow from operating activities amounted to MSEK -46 (-30) · Cash and cash equivalents at the end of the period amounted to MSEK 240 (425) · In February the peer-reviewed, blinded study to independently validate the clinical performance of IMMray™ PanCan-d was published in Clinical and Translational Gastroenterology · The
